Democrat Congressman Calls For FDA Briefing On Vaccines For Children Under 5

( James Clyburn, the Democratic House Majority Whip and Chairman of the Select Subcommittee on the Coronavirus Crisis, has sought a briefing from the Food and Drug Administration (FDA) on when the agency would be able to approve COVID vaccinations for children under the age of five.
During a meeting with FDA Commissioner Robert Califf on Monday, Clyburn expressed his displeasure with suggestions that the agency might not authorize Moderna’s vaccine for young children until the summer.
Clyburn expressed concern that waiting so long might cause immunizations for the youngest infants to be delayed “by weeks” in his letter.
This year’s coronavirus pandemic was brought to a close by the Food and Drug Administration (FDA) authorizing and approving safe and highly effective vaccines for the vast majority of Americans, which saved millions of lives and allowed the country to emerge from the crisis phase of the pandemic safely.
Clyburn said millions of young children continue to be vulnerable because no vaccine for children under the age of five has yet been approved.
The congressman said that during the peak of the Omicron variant, children younger than five were admitted to hospitals at a rate about five times higher than the preceding peak, which occurred during the peak of the Delta variety. As a result, he wrote to request a staff briefing on the current status of coronavirus vaccine candidates for young children.
The letter said in part that the FDA is considering delaying its decision on whether to authorize Moderna’s vaccine for children under six until early summer to be evaluated—and potentially authorized—at the same time as Pfizer’s vaccine for children five and younger. A decision of this nature might delay several weeks in the prospective licensing and delivery of the Moderna vaccine.
Chairman Clyburn requested that the FDA provide a briefing to the Select Subcommittee staff on the status of vaccines for young children by May 9, 2022, including whether recent reports of a potential delay in the FDA’s decision are accurate on the scientific basis or another rationale for any such delay.
Clyburn continues to erroneously call the current shots provided by Big Pharma “immunizations.”
They are not.